Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Airway Obstruction D000402 13 associated lipids
Uremia D014511 33 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Hypoxia D000860 23 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Adenocarcinoma D000230 166 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Zhou Z et al. Mechanisms underlying uridine adenosine tetraphosphate-induced vascular contraction in mouse aorta: Role of thromboxane and purinergic receptors. 2015 Vascul. Pharmacol. pmid:25921923
Lourenço AL et al. Synthesis and antiplatelet activity of antithrombotic thiourea compounds: biological and structure-activity relationship studies. 2015 Molecules pmid:25903367
Sahota T et al. Model-based prediction of the acute and long-term safety profile of naproxen in rats. 2015 Br. J. Pharmacol. pmid:25884765
Violi F et al. Reply: platelet activation and pneumonia: is soluble p-selectin the right marker? 2015 J. Am. Coll. Cardiol. pmid:25857924
Gurbel PA et al. Platelet activation and pneumonia: is soluble p-selectin the right marker? 2015 J. Am. Coll. Cardiol. pmid:25857923
Violi F et al. Reply: myocardial infarction in patients with pneumonia. 2015 J. Am. Coll. Cardiol. pmid:25857922
Karamouzis I et al. Enhanced oxidative stress and platelet activation in patients with Cushing's syndrome. 2015 Clin. Endocrinol. (Oxf) pmid:24923553
Willenberg I et al. Determining cyclooxygenase-2 activity in three different test systems utilizing online-solid phase extraction-liquid chromatography-mass spectrometry for parallel quantification of prostaglandin E(2), D(2) and thromboxane B(2). 2015 J Chromatogr A pmid:25777050
Wang J et al. Prevention of atherosclerosis by Yindan Xinnaotong capsule combined with swimming in rats. 2015 BMC Complement Altern Med pmid:25886942
Hill TL et al. The effect of tramadol and indomethacin coadministration on gastric barrier function in dogs. 2014 May-Jun J. Vet. Intern. Med. pmid:24684670
Yu C et al. Effects of danshensu on platelet aggregation and thrombosis: in vivo arteriovenous shunt and venous thrombosis models in rats. 2014 PLoS ONE pmid:25375124
Salazar F et al. Renal effects induced by prolonged mPGES1 inhibition. 2014 Am. J. Physiol. Renal Physiol. pmid:24197070
Kawai VK et al. Suboptimal inhibition of platelet cyclooxygenase 1 by aspirin in systemic lupus erythematosus: association with metabolic syndrome. 2014 Arthritis Care Res (Hoboken) pmid:24022862
Elsheikh W et al. Enhanced chemopreventive effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer. 2014 Nitric Oxide pmid:24747869
Suarez-Kurtz G Impact of CYP2C9*3/*3 genotype on the pharmacokinetics and pharmacodynamics of oxicam NSAIDs. 2014 Pharmacogenet. Genomics pmid:25003537
Lee HI et al. Response to Suarez-Kurtz's comments on strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals. 2014 Pharmacogenet. Genomics pmid:25003538
Shan MQ et al. [Comparative study on effects of Rubiae Radix et Rhizoma and carbonized Rubiae Radix et Rhizoma on acute blood stasis rat model]. 2014 Zhongguo Zhong Yao Za Zhi pmid:24946554
Zhou K et al. A CAPE analogue as novel antiplatelet agent efficiently inhibits collagen-induced platelet aggregation. 2014 Pharmazie pmid:25158573
Shimizu T et al. Up-regulation of Kv7.1 channels in thromboxane A2-induced colonic cancer cell proliferation. 2014 Pflugers Arch. pmid:23995773
DeFilippis AP et al. Fatty acids and TxA(2) generation, in the absence of platelet-COX-1 activity. 2014 Nutr Metab Cardiovasc Dis pmid:24370448
Togna AR et al. 4-Methylcoumarin derivatives with anti-inflammatory effects in activated microglial cells. 2014 Biol. Pharm. Bull. pmid:24389482
Osmond DA et al. Clopidogrel preserves whole kidney autoregulatory behavior in ANG II-induced hypertension. 2014 Am. J. Physiol. Renal Physiol. pmid:24477682
Cathcart MC et al. Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer. 2014 Biochim. Biophys. Acta pmid:24480048
Umar A et al. Effect of Ocimum basilicum L. on cyclo-oxygenase isoforms and prostaglandins involved in thrombosis. 2014 J Ethnopharmacol pmid:24412551
Sahota T et al. Model-based analysis of thromboxane Bâ‚‚ and prostaglandin Eâ‚‚ as biomarkers in the safety evaluation of naproxen. 2014 Toxicol. Appl. Pharmacol. pmid:24667227
Gonçalves LH et al. Acetylsalicylic acid therapy: influence of metformin use and other variables on urinary 11-dehydrothromboxane B2 levels. 2014 Clin. Chim. Acta pmid:24316050
Jiménez-Romero C et al. Dactyloditerpenol acetate, a new prenylbisabolane-type diterpene from Aplysia dactylomela with significant in vitro anti-neuroinflammatory activity. 2014 Bioorg. Med. Chem. Lett. pmid:24279991
Lee HI et al. Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals. 2014 Pharmacogenet. Genomics pmid:24322170
Voisin V et al. Protection of Wistar-Furth rats against postischaemic acute renal injury: role for nitric oxide and thromboxane? 2014 Clin. Exp. Pharmacol. Physiol. pmid:25115485
Chou YI et al. Correlations of platelet-derived microparticles with thromboxane B2, platelet-activating factor, endothelin-1, and neutrophil to lymphocyte ratio in patients with coronary intermediate lesions. 2014 Biomarkers pmid:25391885
Zhu Y et al. Effects and mechanisms of Fenofibrate on the secretion of vascular endothelial contraction factors in hypertensive rats. 2014 Genet. Mol. Res. pmid:25078582
Tachi M et al. Mass spectrometric determination of prostanoids in rat hypothalamic paraventricular nucleus microdialysates. 2014 Auton Neurosci pmid:24447364
Wang Y et al. DanQi Pill protects against heart failure through the arachidonic acid metabolism pathway by attenuating different cyclooxygenases and leukotrienes B4. 2014 BMC Complement Altern Med pmid:24555740
Fuentes E et al. A novel role of Eruca sativa Mill. (rocket) extract: antiplatelet (NF-κB inhibition) and antithrombotic activities. 2014 Nutrients pmid:25514563
Santos-Gallego CG and Badimon JJ The sum of two evils: pneumonia and myocardial infarction: is platelet activation the missing link? 2014 J. Am. Coll. Cardiol. pmid:25444148
Cangemi R et al. Platelet activation is associated with myocardial infarction in patients with pneumonia. 2014 J. Am. Coll. Cardiol. pmid:25444147
Shinohara M et al. Cell-cell interactions and bronchoconstrictor eicosanoid reduction with inhaled carbon monoxide and resolvin D1. 2014 Am. J. Physiol. Lung Cell Mol. Physiol. pmid:25217660
Hong S et al. Maresin-like lipid mediators are produced by leukocytes and platelets and rescue reparative function of diabetes-impaired macrophages. 2014 Chem. Biol. pmid:25200603
Tong B et al. [Atorvastatin inhibits platelet aggregation and activation following carotid balloon injury in cholesterol-fed rabbits]. 2014 Nan Fang Yi Ke Da Xue Xue Bao pmid:25176087
Kaplon-Cieslicka A et al. Younger age, higher body mass index and lower adiponectin concentration predict higher serum thromboxane B2 level in aspirin-treated patients with type 2 diabetes: an observational study. 2014 Cardiovasc Diabetol pmid:25123549
Hayashi G et al. Frataxin deficiency increases cyclooxygenase 2 and prostaglandins in cell and animal models of Friedreich's ataxia. 2014 Hum. Mol. Genet. pmid:25104852
Floyd CN et al. Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects. 2014 Br J Clin Pharmacol pmid:25099258
Zhu SH et al. Protective effect of indomethacin in renal ischemia-reperfusion injury in mice. 2014 J Zhejiang Univ Sci B pmid:25091992
Basili S et al. Aspirin reload before elective percutaneous coronary intervention: impact on serum thromboxane b2 and myocardial reperfusion indexes. 2014 Circ Cardiovasc Interv pmid:25074252
Lattanzio S et al. Circulating dickkopf-1 in diabetes mellitus: association with platelet activation and effects of improved metabolic control and low-dose aspirin. 2014 J Am Heart Assoc pmid:25037197
Santilli F et al. Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment. 2014 J Am Heart Assoc pmid:25037196
Patrignani P et al. Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. 2014 J. Thromb. Haemost. pmid:24942808
Mayer AM et al. Vibrio vulnificus MO6-24/O lipopolysaccharide stimulates superoxide anion, thromboxane Bâ‚‚, matrix metalloproteinase-9, cytokine and chemokine release by rat brain microglia in vitro. 2014 Mar Drugs pmid:24675728
van den Elsen LW et al. Dietary fish oil improves endothelial function and lowers blood pressure via suppression of sphingolipid-mediated contractions in spontaneously hypertensive rats. 2014 J. Hypertens. pmid:24569415
Reddoch KM et al. Hemostatic function of apheresis platelets stored at 4°C and 22°C. 2014 Shock pmid:24169210